{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"condition":["Patient with metastatic colorectal cancer","Colorectal cancer Duke's D"],"disease":["Patient With Metastatic Colorectal Cancer","Colorectal Cancer Duke's D"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2535860"],"location":["Denmark"],"study_start_month":["9"],"keyword":["Regorafenib","irinotecan","bevacizumab","panitumomab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.","description":"Primary objectives: Overall survival between the two groups","dates":{"creation":"2016-09-15"},"accession":"2535860","cross_references":{"EU Clinical Trials Register":["2016-002222-37"]}}